Iqure’s EAAT2 modulator gains IRB clearance for first-in-human study
March 17, 2025
Iqure Pharma Inc. has received institutional review board (IRB) approval for a first-in-human study of iQ-007 in healthy volunteers. This follows recent formal approval from the Human Research Ethics Committee (HREC) in Australia for the phase I study, which is expected to begin next month.